The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning

Bone Marrow Transplantation

Volumn 28, Issue 8, 2001, Pages 737-742

  Johansson, J E ^a   Brune, M ^a   Ekman, T ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic; Gastro intestinal toxicity; Gut mucosa barrier; Haemopoietic stem cell transplantation; Intestinal permeability; Reduced intensity conditioning

Indexed keywords

ANTIBIOTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDETATE CHROMIUM CR 51; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYELOABLATIVE AGENT; THYMOCYTE ANTIBODY;

ADULT; ALLOGRAFT; ARTICLE; ASSAY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTHESIS; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFUSION; INTESTINE ABSORPTION; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; MALE; PATHOGENESIS; PERMEABILITY BARRIER; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ADULT; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; BUSULFAN; CYCLOPHOSPHAMIDE; FEMALE; GASTRIC MUCOSA; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PERMEABILITY; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 0035187687     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703230     Document Type: Article

References (40)

1. The gut mucosal barrier in bone marrow transplantation
2. Gastro-intestinal toxicity related to bone marrow transplantation: Disruption of the intestinal barrier precedes clinical findings
3. Bacterial translocation from the gastrointestinal tract of mice receiving immunosuppressive chemotherapeutic agents
4. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease
5. The effect of methotrexate (MTX) on the small intestine of the mouse. IV. The Golgi apparatus, phosphatases and esterases
6. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: Role of conditioning application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F)
7. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice
8. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines
9. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia
10. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice
11. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation
12. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
13. Low-intensity conditioning regimen for related donor allogeneic peripheral blood stem cell (PBSC) transplant using low-dose (550 cGy) high dose rate (30 cGy/min) single-exposure total body irradiation (TBI)
14. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitorcell transplantation as treatment for lymphoid malignancies
15. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect
16. A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test
17. Reporting results of cancer treatment
18. 1994 Consensus Conference on Acute GVHD Grading
19. Intestinal permeability during chemotherapy for childhood tumours
20. Intestinal permeability in patients with acute myeloid leukemia
21. Small bowel function in acute lymphoblastic leukaemia
22. Abnormal intestinal permeability to sugars in villous atrophy
23. Assessment of intestinal permeability in the experimental rat with [3H]cellobiotol and [14C]mannitol
24. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease
25. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation
26. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease
27. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation
28. ICAM-1 expression on epidermal keratinocytes in cutaneous graft-versus-host disease
29. Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers
30. Effects of tumor necrosis factor on the interferon-gamma-induced major histocompatibility complex class II antigen expression by human endothelial cells
31. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
32. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
33. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies
34. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide
35. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis
36. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate
37. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality
38. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract
39. Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor
40. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy